Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Time-To-Loss Of Virologic Response Acceptable Endpoint For HIV Drugs-FDA

Executive Summary

Traditional approval of antiretroviral drugs may be based on clinical trials using a primary endpoint of time-to-loss of virologic response or on an endpoint of the proportion of patients whose HIV RNA levels fall below the acceptable assay level, a draft guidance released by FDA states.

You may also be interested in...



HIV Trials Should Focus On Pre-Treated Patients, FDA Guidance Says

FDA is encouraging sponsors of HIV therapies to conduct more clinical trials in treatment-experienced patients

HIV Trials Should Focus On Pre-Treated Patients, FDA Guidance Says

FDA is encouraging sponsors of HIV therapies to conduct more clinical trials in treatment-experienced patients

HIV "Salvage" Drug Efficacy May Be Shown With Half-Log Drop In Viral Load

A .5-log drop in viral load may be an optimal endpoint for testing "salvage" therapies in treatment-experienced HIV patients, FDA's Antiviral Drugs Advisory Committee concluded.

UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel